For the quarter ending 2025-09-30, CHE had -$120,152K decrease in cash & cash equivalents over the period. $66,030K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 64,237 | 124,250 |
| Depreciation and amortization | 16,234 | 32,277 |
| Stock option expense | 6,067 | 18,307 |
| Benefit for deferred income taxes | -3,016 | -13,243 |
| Noncash long-term incentive compensation | -216 | 3,273 |
| Litigation settlements | 1,850 | - |
| Noncash directors' compensation | 0 | 1,123 |
| Amortization of debt issuance costs | 81 | 160 |
| Increase in accounts receivable | 30,937 | 13,466 |
| (increase)/decrease in inventories | -910 | 955 |
| Increase in prepaid expenses | 1,371 | 7,232 |
| Increase/(decrease) in accounts payable and other current liabilities | 22,551 | -12,449 |
| Change in current income taxes | 8,602 | -10,764 |
| Net change in lease assets and liabilities | 504 | 72 |
| Decrease/(increase) in other assets | 6,378 | -48,426 |
| Increase in other liabilities | 4,834 | 1,521 |
| Other sources | 445 | 194 |
| Net cash provided by operating activities | 83,389 | 171,350 |
| Capital expenditures | 17,359 | 29,088 |
| Proceeds from sale of fixed assets | 3,271 | 480 |
| Business combinations, net of cash acquired | 0 | 225 |
| Other uses | 146 | 322 |
| Net cash used by investing activities | -14,234 | -29,155 |
| Purchases of treasury stock | 180,776 | 76,168 |
| Proceeds from exercise of stock options | 0 | 27,152 |
| Dividends paid | 8,654 | 14,542 |
| Capital stock surrendered to pay taxes on stock-based compensation | 0 | 8,484 |
| Change in cash overdrafts payable | 301 | 309 |
| Other sources/(uses) | -178 | 1,092 |
| Net cash used by financing activities | -189,307 | -70,641 |
| Decrease in cash and cash equivalents | -120,152 | 71,554 |
| Cash and cash equivalents at beginning of period | 178,350 | - |
| Cash and cash equivalents at end of period | 129,752 | - |
CHEMED CORP (CHE)
CHEMED CORP (CHE)